Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).

Debra L. Richardson,Minal Barve,James Strauss,Susanna Varkey Ulahannan,Kathleen N. Moore,Erika Paige Hamilton,Melissa Lynne Johnson,Kyriakos P. Papadopoulos,Corrine Zarwan,Charles K Anderson,Joseph Buscema,Deborah B. Doroshow,William Jeffery Edenfield,Ursula A. Matulonis,Timothy F. Burns,Dirk Huebner,Valerie M. Jansen,Rebecca Mosher,Donna Jarlenski,Anthony W. Tolcher

Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).

2020

3549Background: XMT-1536 is a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, broadly expressed in NSCLC and ovarian cancer. XMT-1536 utilizes the Dolaflexin p...

Keywords:

Oncology
Internal medicine
Metastatic ovarian cancer
Medicine
previously treated
non-small cell lung cancer (NSCLC)
Antibody-drug conjugate
in patient
Biomarker (medicine)
Pathology
Ovarian cancer
Phosphate transport
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations